Comparison of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee

ClinicalTrials.gov ID: NCT00139295

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00139295. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Comparison of the Efficacy and Safety of Hylastan to Methylprednisolone Acetate in Patients With Symptomatic Osteoarthritis of the Knee

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a clinical study to investigate the safety and efficacy of hylastan in treating patients with symptomatic osteoarthritis (OA) of the knee.

Study identification

NCT ID: NCT00139295
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Genzyme, a Sanofi Company; Industry
Enrollment: Not listed

Conditions and interventions

Conditions

Osteoarthritis, Knee

Interventions

Hylastan Device

Device

Eligibility (public fields only)

Age range: 40 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2004 (Type not available)
Primary completion: Not listed
Completion: Sep 2007 (Actual)
Last update posted: Feb 5, 2014

2004 – 2007

United States locations

U.S. sites: 15
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
Capstone Clinical Trials, Inc	Birmingham	Alabama	35209	—
Hope Research Institute, LLC	Phoenix	Arizona	85050	—
Tucson Orthopedic Institute, PC	Tucson	Arizona	85712	—
Orthopaedic Specialties of Tampa Bay	Clearwater	Florida	33756	—
Northwestern Center for Clinical Research	Chicago	Illinois	60611	—
Midwest Orthopedics at Rush University Medical Center	Chicago	Illinois	60612	—
Rockford Health Physicians	Rockford	Illinois	61103	—
Bluegrass Orthopaedics/Bluegrass Musculoskeletal Research	Lexington	Kentucky	40509	—
Orthopedic Specialists of Louisiana	Shreveport	Louisiana	71101	—
Arthritis & Osteoporosis Center of Maryland	Frederick	Maryland	21702	—
Clinical Pharmacology Study Group	Worcester	Massachusetts	01610	—
Orthopedic Center for Joint Replacement and Sports	Grants Pass	Oregon	97527	—
Coastal Orthopedic Associates	Conway	South Carolina	29526	—
Unlimited Research	San Antonio	Texas	78217	—
Arthritis Northwest	Seattle	Washington	98166	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00139295, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 5, 2014 · Synced Nov 15, 2026